Biotronik's ICD home monitoring cuts inappropriate shocks in half

December 18, 2012 by MassDevice staff

Biotronik's ECOST study shows that the device maker's ICD home monitoring reduces inappropriate shocks by half and helps extend device battery life.

Biotronik logo

Cardiovascular medical device maker Biotronik unveiled clinical results from its Effectiveness & Cost of ICD Follow-Up Schedule with Telecardiology trial, which showed that the company's home monitoring system reduced inappropriate implantable cardioverter defibrillator shocks by 52% while extending the device's battery-life.

"Developing safe, innovative, effective therapies to improve patient health is Biotronik's number 1 priority," Biotronik international president Christoph Böhmer said in prepared remarks. "Biotronik Home Monitoring enhances the patient's quality of life and simplifies patient treatment."

Sign up to get our free newsletters delivered right to your inbox.

The study was based on 433 patients from 43 sites throughout France, who were followed over a period of 27 months.

The 221 home-monitored patients were brought in to an ambulatory department once per year and the 212 control patients underwent in-office visits every 6 months, according to a press release.

Researchers found that home-monitored patients received 71% fewer shocks over a period of 2 years and 52% fewer inappropriate shocks compared with the control group, Biotronik reported.

The ECOST study also showed a 76% reduction in the number of device capacitor charges for the home monitoring group, which could help protect ICD battery life and extend device longevity, according to the press release.

That's more good news for Biotronik, which recently landed a few regulatory wins for other heart devices.